As of Friday close, BIOLASE Inc.’s (NASDAQ:BIOL) stock traded at $0.08. The average number of shares traded per day over the past five days has been 14,868,080 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.0805 fall in that time frame. In the last twenty days, the average volume was 5,643,120, while in the previous 50 days, it was 3,292,638.
Since last month, BIOL stock retreated -61.43%. Shares of the company fell to $0.0710 on 05/24/23, the lowest level in the past month. A 52-week high of $5.94 was reached on 01/09/23 after having rallying from a 52-week low of $0.07. Since the beginning of this year, BIOL’s stock price has dropped by -87.54% or -$0.5690, and marked a new high 3 times. However, the stock has declined by -98.64% since its 52-week high.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
BIOL stock investors should be aware that BIOLASE Inc. (BIOL) stock had its last reported insider trading activity 171 days ago on Dec 07. LORD JONATHAN T MD, the Director of the company, disposed of 3,537 shares for $0.75 on Dec 07. It resulted in a $2,653 divestment by the insider.
The stock’s beta is 1.39. Besides these, the trailing price-to-sales (P/S) ratio of 0.05, the price-to-book (PB) ratio of 0.32.
In the three months ended March 30, BIOLASE Inc.’s quick ratio stood at 0.70, while its current ratio was 1.70, showing that the company is not able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending March 30 was 1.52, and the total debt-to-equity ratio was 1.70. On the profitability front, the trailing twelve-month gross margin is 29.80% percent. In the year ended March 30, operating margins totaled -54.10%. Based on annual data, BIOL earned $15.91 million in gross profit and brought in $48.46 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -136.10%. Return on equity (ROE) for the past 12 months was -244.90%.
In BIOLASE Inc.’s quarter-end financial report for March 30, it reported total debt of $12.5 million. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. BIOL’s revenue rose 2.87% to $14.05 million during the quarter, while net income inched up to $10.47 million. While analysts expected BIOLASE Inc. to report -$0.2 quarterly earnings, the actual figure was -$0.18 per share. During the quarter, the company generated -$5.04 million in EBITDA. The liabilities of BIOLASE Inc. were 33.79 million at the end of its most recent quarter ended March 30, and its total debt was $16.1 million. The value of shareholders’ equity is $27.73 million.
This quick technical analysis looks at BIOLASE Inc.’s (BIOL) price momentum. With a historical volatility rate of 229.13%, the RSI 9-day stood at 18.72% on 26 May.
With respect to its five-day moving average, the current BIOLASE Inc. price is down by -49.85% percent or -$0.0805. At present, BIOL shares trade -67.60% below its 20-day simple moving average and -88.59% percent below its 100-day simple moving average. However, the stock is currently trading approximately -78.55% below its SMA50 and -98.46% below its SMA200.
Stochastic coefficient K was 4.27% and Stochastic coefficient D was 9.77%, while ATR was 0.0378. Given the Stochastic reading of 4.00% for the 14-day period, the RSI (14) reading has been calculated as 24.73%. As of today, the MACD Oscillator reading stands at -0.0521, while the 14-day reading stands at -0.0813.
BIOLASE Inc. (BIOL) has been rated Buy by analysts. According to 0 brokerage firms, BIOL is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate BIOLASE Inc. stock as buy, with 4 recommending it as overweight.
With a median target price of $1.25, the current consensus forecast for the stock is $0.10 – $10.00. Based on these forecasts, analysts predict BIOLASE Inc. (BIOL) will achieve an average price target of $3.15.